CVRx (CVRX) Gains from Investment Securities (2020 - 2021)
CVRx (CVRX) posted Gains from Investment Securities of -$1.8 million for Q3 2021, down 116.12% on a QoQ basis from $11.5 million in Q2 2021, and down 398.92% year-over-year from $617558.8 in Q3 2020.
Powered by 
Analysis
CVRx (CVRX) Gains from Investment Securities (2020 - 2021) Analysis & Trends
CVRx has reported Gains from Investment Securities for 2 years, with the latest figure at -$1.8 million in Q3 2021.
- On a quarterly basis, Gains from Investment Securities fell 398.92% year-over-year to -$1.8 million in Q3 2021; TTM through Jun 2022 was -$1.8 million, a 111.89% decrease from a year earlier, with the FY2021 full-year figure at $13.3 million, up 3483.29% from the prior year.
- Gains from Investment Securities was -$1.8 million for Q3 2021 at CVRx, down from $11.5 million in the prior quarter.
- The five-year high for Gains from Investment Securities was $11.5 million in Q2 2021, with the low at -$1.8 million in Q3 2021.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.04 Bn | 177.44 Bn | 7.27 Bn |
| 2 | Intuitive Surgical | 125.02 Bn | 119.81 Bn | 1.96 Bn |
| 3 | Medtronic | 117.84 Bn | 109.02 Bn | 6.34 Bn |
| 4 | Stryker | 105.50 Bn | 102.02 Bn | 4.50 Bn |
| 5 | Boston Scientific | 66.27 Bn | 65.73 Bn | 3.85 Bn |
| 6 | Edwards Lifesciences | 49.60 Bn | 45.35 Bn | 1.35 Bn |
| 7 | Alcon | 33.70 Bn | 32.24 Bn | 1.68 Bn |
| 8 | Dexcom | 32.06 Bn | 30.11 Bn | 830.00 Mn |
| 9 | Steris | 21.02 Bn | 20.54 Bn | 684.20 Mn |
| 10 | CVRx | 75.57 Mn | 10.98 Mn | 13.72 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2021 | -1.85 Mn |
| Jun 30, 2021 | 11.45 Mn |
| Mar 31, 2021 | 3.69 Mn |
| Dec 31, 2020 | 758,000.00 |
| Sep 30, 2020 | -370,000.00 |